^
    over3years
    In 454 patients transplanted 2013-2018 we clearly show clinical utility for residual FLT3-ITD and/or NPM1 mutation testing pre-alloHCT. This is definitive and the largest dataset of AML NGS-MRD put together & has advantage of being focused on specific subset and context of use. ()
    Clinical • Next-generation sequencing
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1)
    |
    FLT3-ITD mutation • NPM1 mutation
    |
    NPM1 Mutation Assay